ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Dermatitis exfoliative,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
1,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
3,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
4,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
4,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,3,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
4,4,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
4,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
5,1,Adrenal insufficiency,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
5,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
5,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
6,1,Diplopia,Visual disorders NEC,Vision disorders,Eye,N
6,2,IIIrd nerve paralysis,Eye movement disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
6,3,Tumour marker increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
7,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
7,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
7,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
8,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
8,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
8,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
8,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
9,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
10,1,Pituitary-dependent Cushing's syndrome,Anterior pituitary hyperfunction,Hypothalamus and pituitary gland disorders,Endo,N
10,2,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
11,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
12,1,Ketoacidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
13,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
13,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
14,1,Diabetic ketoacidosis,Diabetic complications NEC,Diabetic complications,Metab,N
14,2,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
15,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
15,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
